Sarepta resumes shipping of gene therapy Elevidys to patients who can walk
Sarepta is facing intense scrutiny following the death of two non-ambulatory teenage boys associated with Elevidys.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.